MedTrace Logo

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

NCT05315258 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 850

Last updated 2025-07-17

No results posted yet for this study

Summary

Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.

This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.

Conditions

  • Melanoma (Skin)
  • Melanoma, Uveal

Interventions

DRUG

Tebentafusp

Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.

Sponsors & Collaborators

  • Immunocore Ltd

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Mark Middleton · Consultant Medical Oncologist and Professor of Experimental Cancer Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2026-12-30
Completion
2027-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05315258 on ClinicalTrials.gov